journal article·2020-12-30

High-Performance Dual Combination Therapy for Cancer Treatment with Hybrid Membrane-Camouflaged Mesoporous Silica Gold Nanorods

Huan Li, Qingsheng Peng, Langyu Yang, Yinshan Lin, Sheng Chen, Yuyan Qin, Songpei Li, Xiyong Yu, Lingmin Zhang

ACS Applied Materials & Interfaces· Volume 12· Issue 52
Publisher page

Abstract

Conventional chemotherapy usually induces significant side effects due to its inability to discriminate between cancer and normal cells. Moreover, the efficacy of cancer elimination is still unsatisfied. Here, we fabricated a nanocomposite enabling high-performance dual combination therapy (chemo/photothermal therapy). This style of novel nanocomposites was constructed with doxorubicin (DOX)-loaded mesoporous silica gold (MSG) nanorods, which were further camouflaged with hybrid membranes derived from HeLa cells and red blood cells (HRMSGD). The hybrid membrane-camouflaged structure showed enhanced circulation lifetime and cell line-specific delivery of chemotherapeutics both in vitro and in vivo. The dual combination therapy by HRMSGD showed an unattainable therapeutic effect, compared with a single treatment, and inhibited tumor growth significantly. Furthermore, the nanoplatforms were photoacoustic-responsive, which showed real-time and noninvasive tracking capability. The present study established nanoplatforms with hybrid cell membrane-camouflaged multifunctional gold nanorods, which realized the combination of homotypic targeting, noninvasive tracking, chemotherapy, and photothermal therapy. To the best of our knowledge, this is the first study to use a natural membrane to camouflage mesoporous silica-modified gold nanorods, which opened a new avenue for cancer treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China

Funding

State Key Laboratory of Respiratory Disease · National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Key Laboratory of Molecular Target and Clinical Pharmacology, Guangzhou Medical University

References (24)

Show source-provided references
1. 10.1038/s41571-019-0267-410.1038/s41571-019-0267-4 ↗
2. 10.1038/s41565-019-0567-y10.1038/s41565-019-0567-y ↗
3. 10.1016/j.jconrel.2015.09.02910.1016/j.jconrel.2015.09.029 ↗
4. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
5. 10.1002/smll.20200274810.1002/smll.202002748 ↗
6. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
7. 10.1021/nn201010q10.1021/nn201010q ↗
8. 10.1021/nn401168610.1021/nn4011686 ↗
9. 10.1021/ja412735p10.1021/ja412735p ↗
10. 10.1021/acs.bioconjchem.6b0056910.1021/acs.bioconjchem.6b00569 ↗
11. 10.1016/j.jconrel.2015.07.01910.1016/j.jconrel.2015.07.019 ↗
12. 10.1002/adhm.20190077210.1002/adhm.201900772 ↗
13. 10.1002/smll.20200295010.1002/smll.202002950 ↗
14. 10.1038/nmat464410.1038/nmat4644 ↗
15. 10.1021/acsami.0c0755910.1021/acsami.0c07559 ↗
16. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
17. 10.1002/adma.20160217310.1002/adma.201602173 ↗
18. 10.1021/acsnano.6b0469510.1021/acsnano.6b04695 ↗
19. 10.1002/adma.20160620910.1002/adma.201606209 ↗
20. 10.1056/NEJMoa161588710.1056/NEJMoa1615887 ↗
21. 10.1016/j.biomaterials.2015.05.00110.1016/j.biomaterials.2015.05.001 ↗
22. 10.1021/nn901181c10.1021/nn901181c ↗
23. 10.1021/acsnano.7b0835510.1021/acsnano.7b08355 ↗
24. 10.1021/nl072741510.1021/nl0727415 ↗